Oncology
2 drugs are in development for Marginal Zone Lymphoma.
- Companies
- 2
- Clinical trials
- 29
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Marginal Zone Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(2)
| Drug | Company |
|---|---|
| CTX112 | CRISPR Therapeutics AG (CRSP) |
| prt2527 | Prelude Therapeutics Inc (PRLD) |
About this indication
Marginal Zone Lymphoma context
Oncology·MeSH: Lymphoma, B-Cell, Marginal Zone (D018442)
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Marginal Zone Lymphoma?
BioSniper tracks 2 drugs in development for Marginal Zone Lymphoma across 2 companies.
How many clinical trials target Marginal Zone Lymphoma?
There are 29 clinical trials targeting Marginal Zone Lymphoma tracked by BioSniper.
What is the prevalence of Marginal Zone Lymphoma?
The estimated prevalence of Marginal Zone Lymphoma is approximately 56.0 per 100,000 population.